GT Medical Technologies
Developer and sponsor of a tile-based, implantable brachytherapy system for operable brain tumors. The company produces bioresorbable collagen tiles embedded with radioactive seeds (cesium-131) that are implanted at the time of surgical resection to deliver localized radiation. Activities documented on the site include multi-center randomized clinical trials (including a phase 3 trial with central radiology review), a patient registry for real-world outcomes, peer-reviewed publications and conference presentations, treatment center designation and onboarding programs, and commercial financing to support market expansion.
Industries
Nr. of Employees
medium (51-250)
GT Medical Technologies
Patents
Products
Tile-based implantable brachytherapy system
An implantable, bioresorbable collagen tile embedded with multiple cesium-131 radioactive seeds designed for placement in the surgical resection cavity to deliver localized radiation over several weeks.
GammaTile
FDA-cleared, bioresorbable collagen tile embedded with radiation sources designed for operable brain tumors, delivering targeted radiation right at the source immediately following surgical removal.
Tile-based implantable brachytherapy system
An implantable, bioresorbable collagen tile embedded with multiple cesium-131 radioactive seeds designed for placement in the surgical resection cavity to deliver localized radiation over several weeks.
GammaTile
FDA-cleared, bioresorbable collagen tile embedded with radiation sources designed for operable brain tumors, delivering targeted radiation right at the source immediately following surgical removal.
Services
Sponsor and coordinate multi-center randomized trials and registries for tile-based implantable brachytherapy.
Patient-facing navigation to identify treatment centers and downloadable educational materials to support decision making.
Designation program and onboarding resources for treatment centers, including training materials and operational support for integrating the implant procedure.
Centralized fact sheets, press materials, media assets and KOL coordination to communicate clinical trial results and support peer and public dissemination.
Sponsor and coordinate multi-center randomized trials and registries for tile-based implantable brachytherapy.
Patient-facing navigation to identify treatment centers and downloadable educational materials to support decision making.
Designation program and onboarding resources for treatment centers, including training materials and operational support for integrating the implant procedure.
Centralized fact sheets, press materials, media assets and KOL coordination to communicate clinical trial results and support peer and public dissemination.
Expertise Areas
- Tile-based implantable brachytherapy for brain tumors
- Clinical trial management (multi-center RCTs and registries)
- Intraoperative implantable radiation therapies
- Radiation dosimetry design for implantable sources
Key Technologies
- Tile-based implantable brachytherapy
- Cesium-131 sealed-source implants
- Bioresorbable collagen implant materials
- Intraoperative surgical implantation workflows
News & Updates
Phase 3 randomized controlled trial data presented at ASCO showing superior surgical bed recurrence-free survival and longer overall survival for tile-based intraoperative brachytherapy versus resection plus post-operative stereotactic radiation in newly diagnosed operable brain metastases.
Announced completion of an oversubscribed Series E equity financing to advance commercial treatment for operable brain tumors.
Multiple Series D financing events announced in 2025, including a $37 million raise and a subsequent final close of $53 million to support U.S. expansion.
Company reported reaching a milestone of 2,000 patients treated with the tile-based implantable therapy.
Publication of clinical data in the Journal of Neuro-Oncology reporting outcomes for the implantable tile-based therapy in recurrent brain metastases.
A series of treatment centers across academic and community hospitals were designated under the company's Center of Excellence program to support clinical adoption and training (designation announcements published between 2025 and 2026).
Phase 3 randomized controlled trial data presented at ASCO showing superior surgical bed recurrence-free survival and longer overall survival for tile-based intraoperative brachytherapy versus resection plus post-operative stereotactic radiation in newly diagnosed operable brain metastases.
Announced completion of an oversubscribed Series E equity financing to advance commercial treatment for operable brain tumors.
Multiple Series D financing events announced in 2025, including a $37 million raise and a subsequent final close of $53 million to support U.S. expansion.
Company reported reaching a milestone of 2,000 patients treated with the tile-based implantable therapy.
Publication of clinical data in the Journal of Neuro-Oncology reporting outcomes for the implantable tile-based therapy in recurrent brain metastases.
A series of treatment centers across academic and community hospitals were designated under the company's Center of Excellence program to support clinical adoption and training (designation announcements published between 2025 and 2026).